Home » Posts tagged with » primary mitochondrial myopathies
Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals gets FDA ODD for REN001 in primary mitochondrial myopathies

Reneo Pharmaceuticals has been granted the orphan drug designation (ODD) for its lead drug candidate REN001 from the US Food and Drug Administration (FDA) for the treatment of primary mitochondrial myopathies (PMM). According to the California-based clinical-stage company, REN001 is a selective PPAR delta agonist, which is being developed for the treatment of genetic myopathies, […]